Related references
Note: Only part of the references are listed.Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial
Elaine C. Siegfried et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2021)
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study
Mette Deleuran et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)
A. Wollenberg et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension
M. J. Cork et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis A Phase 3 Randomized Clinical Trial
Eric L. Simpson et al.
JAMA DERMATOLOGY (2020)
Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation
Audrey Le Floc'h et al.
ALLERGY (2020)
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial
Amy S. Paller et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children
A. Wollenberg et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
The fear of needles: A systematic review and meta-analysis
Jennifer McLenon et al.
JOURNAL OF ADVANCED NURSING (2019)
The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long-standing disease
Patrick M. Brunner et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Update on eosinophilic granulomatosis with polyangiitis
Shunsuke Furuta et al.
ALLERGOLOGY INTERNATIONAL (2019)
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
Claus Bachert et al.
LANCET (2019)
Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape
Mark Boguniewicz et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2018)
Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement
A. M. Drucker et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE)
M. de Bruin-Weller et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
Klaus F. Rabe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
M. Castro et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Blocking IL-4Ra with dupilumab prevents lung inflammation in a mouse asthma model
Jamie Orengo et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Commonality of the IL-4/IL-13 pathway in atopic diseases
Namita A. Gandhi et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2017)
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
Andrew Blauvelt et al.
LANCET (2017)
Targeting key proximal drivers of type 2 inflammation in disease
Namita A. Gandhi et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
E. L. Simpson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management
Matthieu Groh et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2015)
Important roles of platelets as immune cells in the skin
Risa Tamagawa-Mineoka
JOURNAL OF DERMATOLOGICAL SCIENCE (2015)
Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes
Lynn E. Macdonald et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice
Andrew J. Murphy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis
Julia K. Gittler et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
Elevated Platelet Activation in Patients with Atopic Dermatitis and Psoriasis: Increased Plasma Levels of β-Thromboglobulin and Platelet Factor 4
Risa Tamagawa-Mineoka et al.
ALLERGOLOGY INTERNATIONAL (2008)
Share Paper
